EDINBURGH, United Kingdom, May 12, 2005 (PRIMEZONE) -- Stanislaw R. Burzynski, M. D., Ph.D., founder and CEO of the Burzynski Clinic and President of the Burzynski Research Institute, Inc. (OTCBB:BZYR) in Houston, gave a presentation entitled "Targeted Therapy with ANP in Children Less Than 4 Years Old with Inoperable Brain Stem Gliomas (BSG)" to the combined World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association of Neuro-Oncology, May 5-8, 2005.
The objective of the study presented was to evaluate the outcome on a small group of patients younger than 4 years of age diagnosed with BSG and treated with Antineoplastons (ANP) in two FDA and Institutional Review Board monitored Phase II clinical trials. The data resulting from the study indicates a significant percentage of complete responses and long-term survival in that group as a result of treatment with ANP. The overall survival of these patients is 60% at 2 years and 20% at 5 years -- compared to standard therapy results of 7% at 2 years and no survivals at 5 years.
Robert A. Weaver, M.D., C. C. T. I. (Certified Clinical Trial Investigator) of the Burzynski Clinic also gave a presentation entitled "Long-Term Survival in Patients with Glioblastoma Multiforme (GBM) Treated in Phase II Studies with ANP."
The objectives of this study were: 1) to determine the frequency of long-term survival in patients with GBM treated in Phase II studies with Antineoplastons A10 and AS2-1 (ANP); 2) to identify specific factors which influence long-term survival; and 3) to compare survival of patients treated with ANP to that of patients receiving standard treatments. The results indicated that long-term survivability in patients receiving ANP is significantly better than in patients receiving standard therapy (17.7% versus 1.8% respectively). Additionally, ANP is well tolerated and there is no drug-related mortality.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. BRI cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to BRI's ability to obtain regulatory approval for Antineoplastons A10 and AS2-1. BRI does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
The logo for Burzynski Research Institute is available at: http://www.primezone.com/newsroom/prs/?pkgid=1291